Aytu Biopharma (AYTU) Intangibles (2015 - 2026)

Aytu Biopharma (AYTU) has 12 years of Intangibles data on file, last reported at $42.5 million in Q1 2026.

• Intangibles for Q1 2026 came in at $42.5 million, down 40.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $42.5 million (down 40.55% YoY), and the FY2025 annual result was $55.4 million, down 22.48% from the prior year.
• Intangibles declined to $42.5 million in Q1 2026 per AYTU's latest filing, from $43.6 million in the prior quarter.
• Over five years, Intangibles peaked at $89.6 million in Q3 2022 and troughed at $42.5 million in Q1 2026.
• A 5-year average of $63.0 million and a median of $63.5 million in 2023 frame the typical range for Intangibles.
• The sharpest annual moves came in 2022 and 2026: Intangibles jumped 11713.97% in 2022, then tumbled 40.55% in 2026.
• A 5-year view of Intangibles shows it stood at $65.0 million in 2022, then dropped by 14.27% to $55.7 million in 2023, then fell by 10.33% to $50.0 million in 2024, then slipped by 12.77% to $43.6 million in 2025, then decreased by 2.5% to $42.5 million in 2026.
• Business Quant data shows AYTU's Intangibles at $42.5 million in Q1 2026, $43.6 million in Q4 2025, and $55.4 million in Q3 2025.